Concerns about delayed healing with polymer-based drug-eluting stents continue to drive interest in polymer-free designs. A new report in the International Journal of Cardiology provides early one-year results for a polymer-free everolimus-eluting stent used across multiple centers in India.

The interim analysis examined 500 adults enrolled between August 2022 and September 2023 at 33 centers. All adults underwent percutaneous coronary intervention for acute or chronic coronary syndromes. The primary endpoint was TLF at one year, defined as cardiovascular death, clinically driven target-lesion revascularization, and target-vessel myocardial infarction.
The cohort was predominantly men (78%) with a mean age of 61.0 ± 10.9 years. Acute coronary syndromes accounted for 87.4% of presentations. Arterial hypertension was present in 61.8%, diabetes in 46.0%, and dyslipidemia in 53.0%.

At one year, TLF occurred in 1.0% of adults (5 individuals). Cardiovascular death occurred in 0.8%, target-vessel myocardial infarction in 0.4%, and clinically driven target-lesion revascularization in 0.2%. Definite or probable stent thrombosis was reported in 0.6%.
These findings indicate a favorable one-year safety and efficacy profile for polymer-free everolimus-eluting stent technology. The low rates of TLF and stent thrombosis support continued observation of outcomes in broader percutaneous coronary intervention settings.